Combination of high on-treatment platelet aggregation and low deaggregation better predicts long-term cardiovascular events in PCI patients under dual antiplatelet therapy

References

• Hamm CW, Bassand JP, Agewall S. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054
   PubMed Web of Science ®Google Scholar
• King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report if the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008;51:172–209
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: The PCI-CLARITY study. JAMA 2005;294:1224–1232
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Brennan DM, Topol EJ; CREDO Investigators. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47:939–943
   PubMed Web of Science ®Google Scholar
• Müller I, Seyfarth M, Rüdiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85:92–93
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J AM Coll Cardiol 2010;56:919–933
   PubMed Web of Science ®Google Scholar
• Geisler T, Langer H, Wydymus M, Göhring K, Zürn C, Bigalke B, Stellos K, May AE, Gawaz M. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006;27:2420–2425
   PubMed Web of Science ®Google Scholar
• Geisler T, Zürn C, Simonenko R, Rapin M, Kraibooj H, Kilias A, Bigalke B, Stellos K, Schwab M, May AE, et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010;31:59–66
   PubMed Web of Science ®Google Scholar
• Park DW, Lee SW, Yun SC, Song HG, Ahn JM, Lee JY, Kim WJ, Kang SJ, Kim YH, Lee CW, et al. A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug eluting stent implantation. J Am Colll Cardiol 2011;58:2630–2639
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754–762
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J 2007;154:221–231
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Palisaitis DA, Schampaert E, Diodati JG. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thromb Res 2009;124:546–553
   PubMed Web of Science ®Google Scholar
• Maayani S, Tagliente TM, Schwarz T, Martinelli G, Martinez R, Shore-Lesserson L. The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes. Platelets 2001;12(2):83–93
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Büttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560–2564
   PubMed Web of Science ®Google Scholar
• Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A. Effect of glycoprotein IIb–IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998;80:994–1001
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Hochholzer W, Pogatsa-Murray G, Schömig A, Gawaz M. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001; 37:1323–1328
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256--260
   Google Scholar
• Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713–718
   PubMed Web of Science ®Google Scholar
• Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937–943
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Hear J 2009;157:148.e1–148.e5
   PubMed Web of Science ®Google Scholar
• Brendel K, Weigel G, Griesmacher A, Pachinger O, Mair J. Low prevalence of clopidogrel and acetylsalicylic acid resistance in patients with acute myocardial infarction and pantoprazole treatment in everyday practice. Int J Cardiol. 2013 Feb 25. pii: S0167-5273(13)00306-9
   Google Scholar
• Mizia-Stec K, Haberka M, Mizia M, Lasota B, Kunecki M, Gieszczyk K, Chmiel A, Najda J, Kyrcz-Krzemień S, Gąsior Z. Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Pharmacol Rep 2012;64:360–368
   PubMed Web of Science ®Google Scholar
• Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos 2012;33:278–283
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: Implications for coadministration with clopidogrel. Drug Metab Dispos 2011;39:2020–2033
   PubMed Web of Science ®Google Scholar
• Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi MC, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007;100:1199–1206
   PubMed Web of Science ®Google Scholar
• Geisler T, Grass D, Bigalke B, Stellos K, Drosch T, Dietz K, Herdeg C, Gawaz M. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008;6:54–61
   PubMed Web of Science ®Google Scholar
• Kozinski M, Bielis L, Wisniewska-Szmyt J, Boinska J, Stolarek W, Marciniak A, Kubica A, Grabczewska Z, Navarese EP, Andreotti F, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011;22:579–587
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al. Association of cytochrome P450 2C19 geotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–857
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012;125:1276–1287
   PubMed Web of Science ®Google Scholar
• Jaitner J, Stegherr J, Morath T, et al. Stability of the high-on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2010; 105: 107–112
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–933
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011;305:1097–1105
   PubMed Web of Science ®Google Scholar
• Labarthe B, Théroux P, Angioï M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005;46:638–645
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Kleibeuker M, Mieremet N, ten Berg JM, Hackeng CM. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: Peak aggregation or late aggregation? J Thromb Haemost 2007;5:884–886
   PubMed Web of Science ®Google Scholar
• Aradi D, Vorobcsuk A, Lenkey Z, Horváth IG, Komócsi A. Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. Platelets 2010;21:1–10
   PubMed Web of Science ®Google Scholar
• Davis JW, Phillips PE, Yue KT, Lewis HD Jr, Hartman CR. Platelet aggregation. Adult-onset diabetes mellitus and coronary artery disease. JAMA 1978;239:732–734
   PubMed Web of Science ®Google Scholar
• Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999;33:634–639
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–2913
   PubMed Web of Science ®Google Scholar
• Müller K, Aichele S, Herkommer M, Bigalke B, Stellos K, Htun P, Fateh-Moghadam S, May AE, Flather M, Gawaz M, et al. Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease. Atherosclerosis 2010;213:256–262
   PubMed Web of Science ®Google Scholar
• Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, Herdeg C, May AE, Gawaz M. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007;30:372–374
   PubMed Web of Science ®Google Scholar